RedHill Biopharma (RDHL) Gross Margin (2014 - 2023)
RedHill Biopharma's (RDHL) quarterly Gross Margin came in at 55.12% in Q2 2023, up 415.0% year-over-year from 10.7% in Q2 2022, and little changed quarter-over-quarter from 55.21% in Q1 2023.
Powered by 
Analysis
RedHill Biopharma (RDHL) Gross Margin (2014 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported Gross Margin for 9 consecutive years, with 55.12% the latest figure, recorded in Q2 2023.
- On a quarterly basis, Gross Margin rose 415.0% year-over-year to 55.12% in Q2 2023; TTM through Jun 2023 was 42.74%, a 111.0% increase from a year earlier, with the FY2025 full-year figure at 1927.62%, up 186732.0% from the prior year.
- Gross Margin was 55.12% for Q2 2023 at RedHill Biopharma, roughly flat from 55.21% in the prior quarter.
- Over five years, Gross Margin peaked at 75.99% in Q1 2019 and troughed at 62.41% in Q1 2020.
- A 5-year average of 43.77% and a median of 50.7% in 2020 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin tumbled 13840 bps in 2020 and surged 11257 bps in 2021, its largest moves.
- Over 5 years, Gross Margin stood at 50.44% in 2019, then retreated by 0 bps to 50.37% in 2020, then plunged by 75 bps to 12.4% in 2021, then surged by 165 bps to 32.82% in 2022, then surged by 68 bps to 55.12% in 2023.
- The last three Gross Margin figures came in at 55.12% (Q2 2023), 55.21% (Q1 2023), and 32.82% (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 95.97% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 55.12% |
| Mar 31, 2023 | 55.21% |
| Dec 31, 2022 | 32.82% |
| Sep 30, 2022 | 46.15% |
| Jun 30, 2022 | 50.97% |
| Mar 31, 2022 | 51.98% |
| Dec 31, 2021 | 12.40% |
| Sep 30, 2021 | 57.29% |
| Jun 30, 2021 | 50.75% |
| Mar 31, 2021 | 50.17% |
| Dec 31, 2020 | 50.37% |
| Sep 30, 2020 | 50.64% |
| Jun 30, 2020 | 32.11% |
| Mar 31, 2020 | -62.41% |
| Dec 31, 2019 | 50.44% |
| Sep 30, 2019 | 55.10% |
| Jun 30, 2019 | 72.81% |
| Mar 31, 2019 | 75.99% |
| Dec 31, 2018 | 57.03% |
| Sep 30, 2018 | 72.89% |